Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-18T07:53:23.985Z Has data issue: false hasContentIssue false
  • English
  • Français

Real-world implementation and impact of a rapid carbapenemase detection test in an area endemic for carbapenem-resistant Enterobacterales

Published online by Cambridge University Press:  15 February 2021

Alex M. Trzebucki Open the ORCID record for Alex M. Trzebucki [Opens in a new window] ,
Lars F. Westblade ,
Angela Loo ,
Shawn Mazur ,
Stephen G. Jenkins ,
David P. Calfee ,
Michael J. Satlin  and
Matthew S. Simon
Alex M. Trzebucki*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York
Lars F. Westblade
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
Angela Loo
Affiliation:
Department of Pharmacy, NewYork-Presbyterian Hospital, New York, New York
Shawn Mazur
Affiliation:
Department of Pharmacy, NewYork-Presbyterian Hospital, New York, New York
Stephen G. Jenkins
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
David P. Calfee
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York Department of Infection Prevention and Control, NewYork-Presbyterian Hospital, New York, New York
Michael J. Satlin
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York
Matthew S. Simon
Affiliation:
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York Department of Infection Prevention and Control, NewYork-Presbyterian Hospital, New York, New York
*
Author for correspondence: Alex M. Trzebucki, E-mail: trzebucki@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

A retrospective study was conducted to describe the impact of a molecular assay to detect the most common carbapenemase genes in carbapenem-resistant Enterobacterales isolates recovered in culture. Carbapenemases were detected in 69% of isolates, and assay results guided treatment modifications or epidemiologic investigation in 20% and 4% of cases, respectively.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 1 , January 2022 , pp. 92 - 95
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bonomo, R, Burd, E, Conly, J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 2018;66:1290–1297.CrossRefGoogle ScholarPubMed
Martin, A, Fahrbach, K, Zhao, Q, Lodise, T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018;5(7):1–9.CrossRefGoogle ScholarPubMed
Tamma, P, Goodman, K, Harris, A, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 2017;64:257–264.CrossRefGoogle ScholarPubMed
Traczewski, M, Carretto, E, Canton, R, Moore, N. Multicenter evaluation of the Xpert Carba-R assay for detection of carbapenemase genes in gram-negative isolates. J Clin Microbiol 2018;56(8):e00272–18.CrossRefGoogle ScholarPubMed
Satlin, M, Chen, L, Patel, G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017;61(4):e02349–16.CrossRefGoogle ScholarPubMed
Cepheid. Xpert Carba-R in vitro diagnostic medical device. REF GXCARBAR-10 301-2438, Rev F. August 2019.Google Scholar
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 29th informational supplement. CLSI M100-S29. Wayne, PA: CLSI; 2019.Google Scholar
Walters, M, Grass, J, Bulens, S, et al. Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg Infect Dis 2019;25:1281–1288.CrossRefGoogle ScholarPubMed
US Department of Labor Occupational Outlook Handbook, Clinical Technologists and Technicians. Bureau of Labor Statistics website. https://www.bls.gov/ooh/healthcare/clinical-laboratory-technologists-and-technicians.htm. Accessed July 12, 2020.Google Scholar
Jenkins, S, Ledeboer, NA, Westblade, LF, et al. Evaluation of NG-test Carba 5 for rapid phenotypic detection and differentiation of five common carbapenemase families: results of a multicenter clinical evaluation. J Clin Microbiol 2020;58(7):e00344–20.CrossRefGoogle ScholarPubMed
Supplementary material: File

Trzebucki et al. supplementary material

Table S1

Download Trzebucki et al. supplementary material(File)
File 13.7 KB